Search results for "cancer therapy"

showing 10 items of 101 documents

Enhanced adhesion and in situ photothermal ablation of cancer cells in surface-functionalized electrospun microfiber scaffold with graphene oxide

2017

The physicochemical characteristics of a biomaterial surface highly affect the interaction with living cells. Recently, much attention has been focused on the adhesion properties of functional biomaterials toward cancer cells, since is expected to control metastatic spread of a tumor, which is related to good probability containing the progression of disease burden. Here, we designed an implantable poly(caprolactone)-based electrospun microfiber scaffold, henceforth PCLMF-GO, to simultaneously capture and kill cancer cells by tuning physicochemical features of the hybrid surface through nitrogen plasma activation and hetero-phase graphene oxide (GO) covalent functionalization. The surface i…

3003business.product_categoryCancer therapyPharmaceutical ScienceNanotechnologyBiocompatible Materials02 engineering and technologyCell capture010402 general chemistry01 natural scienceslaw.inventionPlasmalawNeoplasmsMicrofiberCell AdhesionHumansCell adhesionGraphene oxideHybrid materialChemistryGrapheneBiomaterialOxidesAdhesionPhotothermal therapyPhototherapy021001 nanoscience & nanotechnology0104 chemical sciencesPolycaprolactoneCancer cellMCF-7 CellsSurface modificationGraphite0210 nano-technologybusiness
researchProduct

Selection and characterization of a novel agonistic human recombinant anti-Trail-R2 minibody with anti-leukemic activity

2009

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising natural anticancer therapeutic agent because through its “death receptors”, TRAIL-R1 and TRAIL-R2, it induces apoptosis in many transformed tumor cells, but not in the majority of normal cells. Hence, agonistic compounds directed against TRAIL death receptors have the potential of being excellent cancer therapeutic agents, with minimal cytotoxicity in normal tissues. Here, we report the selection and characterization of a new single-chain fragment variable (scFv) to TRAIL-R2 receptor isolated from a human phage-display library, produced as minibody (MB), and characterized for the in vitro anti-leukemic tumoricid…

Agonistmedicine.drug_classTRAIL; TRAIL-R2; minibody; anticancer therapyImmunologylymphoma; therapy; recombinant antibodyTRAILApoptosislymphomaCHO CellsCricetulusPeptide LibraryTRAIL-R2CricetinaeImmunoglobulin FragmentmedicineAnimalsHumansImmunology and Allergyrecombinant antibodyanticancer therapyReceptorCytotoxicityImmunoglobulin FragmentsPharmacologytherapyLeukemiaChemistryAnimalChinese hamster ovary cellAntibody-Dependent Cell CytotoxicityminibodyApoptosiIn vitroRecombinant ProteinsReceptors TNF-Related Apoptosis-Inducing LigandCHO CellCell cultureApoptosisImmunologyCancer researchTumor necrosis factor alphaCricetuluHuman
researchProduct

Ag+ Complexes as Potential Therapeutic Agents in Medicine and Pharmacy

2019

Silver is a non-essential element with promising antimicrobial and anticancer properties. This work is a detailed summary of the newest findings on the bioinorganic chemistry of silver, with a special focus on the applications of Ag+ complexes and nanoparticles. The coordination chemistry of silver is given a reasonable amount of attention, summarizing the most common silver binding sites and giving examples of such binding motifs in biologically important proteins. Possible applications of this metal and its complexes in medicine, particularly as antibacterial and antifungal agents and in cancer therapy, are discussed in detail. The most recent data on silver nanoparticles are also summari…

Antifungalsilver nanoparticlesSilvermedicine.drug_classCancer therapyMetal NanoparticlesNanoparticleAntineoplastic Agents02 engineering and technologyPharmacology010402 general chemistry01 natural sciencesBiochemistrySilver(I) complexesSilver nanoparticleCoordination complexStructure-Activity RelationshipAnti-Infective AgentsCoordination ComplexesDrug DiscoverymedicineHumansAmino Acid SequenceAmino AcidsIonsPharmacologychemistry.chemical_classificationMolecular StructureChemistryOrganic Chemistryantibacterial and anticancer activity of Ag+021001 nanoscience & nanotechnologyCombinatorial chemistry0104 chemical sciencescysteine and methionine motifsMolecular Medicine0210 nano-technologyProtein BindingCurrent Medicinal Chemistry
researchProduct

Polyaspartamide-Doxorubicin Conjugate as Potential Prodrug for Anticancer Therapy

2015

Purpose To synthesize a new polymeric prodrug based on ?,?- poly(N-2-hydroxyethyl)(2-aminoethylcarbamate)-d,l-aspartamide copolymer bearing amine groups in the side chain (PHEA-EDA), covalently linked to the anticancer drug doxorubicin and to test its potential application in anticancer therapy. Methods The drug was previously derivatized with a biocompatible and hydrophilic linker, leading to a doxorubicin derivative highly reactive with amino groups of PHEA-EDA. The PHEAEDA- DOXO prodrug was characterized in terms of chemical stability. The pharmacokinetics, biodistribution and cytotoxicity of the product was investigated in vitro and in vivo on human breast cancer MCF-7 and T47D cell lin…

BiodistributionPolymeric prodrugPharmaceutical ScienceBreast NeoplasmsMice SCIDpolymeric prodrugPharmacologyMice Inbred NODCell Line TumorPolyaminesmedicineSide chainAnimalsHumansProdrugsTissue Distributionantitumor activityDoxorubicinPharmacology (medical)BreastAspartamebiodistributionPharmacologyChemistryPHEA-EDAOrganic ChemistryProdrugAnticancer drugPolyaspartamideDoxorubicinMCF-7 CellsMolecular MedicineFemaleAmine gas treatingantitumor activity; biodistribution; doxorubicin; PHEA-EDA; polymeric prodruganti-cancer therapymedicine.drugConjugateBiotechnology
researchProduct

Oxygenation and Bioenergetic Status of Murine Fibrosarcomas

1992

The heterogeneity of cellular response to therapy is a major problem in non-surgical cancer therapy. This heterogeneity is influenced by both the genetic variability between different tumor cells and by epigenetic, physiological factors, such as the local metabolic milieu. A restriction of tumor microcirculation concomitant with regional hypoxia, nutrient depletion, accumulation of lactate, and an intensified tumor acidosis becomes evident during growth of many solid tumors1. These critical factors can greatly influence the efficiency of various non-surgical tumor therapies.

BioenergeticsCritical factorsmedicineCancer therapyCancer researchGenetic variabilityEpigeneticsOxygenationmedicine.symptomBiologyHypoxia (medical)Acidosis
researchProduct

Cancer cell targeting by CAR-T cells: A matter of stemness

2022

Chimeric antigen receptor (CAR)-T cell therapy represents one of the most innovative immunotherapy approaches. The encouraging results achieved by CAR-T cell therapy in hematological disorders paved the way for the employment of CAR engineered T cells in different types of solid tumors. This adoptive cell therapy represents a selective and efficacious approach to eradicate tumors through the recognition of tumor-associated antigens (TAAs). Binding of engineered CAR-T cells to TAAs provokes the release of several cytokines, granzyme, and perforin that ultimately lead to cancer cells elimination and patient’s immune system boosting. Within the tumor mass a subpopulation of cancer cells, known…

CAR-T cell therapycancer stem cellAnti-cancer therapySettore MED/50 - Scienze Tecniche Mediche ApplicateTumor MicroenvironmentImmunotherapySettore MED/46 - Scienze Tecniche Di Medicina Di Laboratorio
researchProduct

A Definitive Pharmacophore Modelling Study on CDK2 ATP Pocket Binders: Tracing the Path of New Virtual High-Throughput Screenings

2020

Cyclin Dependent Kinases-2 (CDK2) are members of serine/threonine protein kinases family. They play an important role in the regulation events of the eukaryotic cell division cycle, especially during the G1 to S phase transition. Experimental evidence indicate that excessive expression of CDK2s should cause abnormal cell cycle regulation. Therefore, since a long time, CDK2s have been considered potential therapeutic targets for cancer therapy. In this work, onehundred and forty-nine complexes of inhibitors bound in the CDK2-ATP pocket were submitted to short MD simulations (10ns) and free energy calculation. Comparison with experimental data (K<sub>i</sub>, K<sub>d</su…

CDK20301 basic medicineComputer scienceATP pocketCancer therapyComputational biologyMolecular dynamicsTracingCommon hits approachInhibitory Concentration 5003 medical and health sciencesMolecular dynamicsAdenosine Triphosphate0302 clinical medicineNeoplasmsDrug DiscoveryHumansProtein Kinase InhibitorsThroughput (business)Eukaryotic cellMM-GBSABinding SitesbiologyCyclin-Dependent Kinase 2Cyclin-dependent kinase 2High-Throughput Screening AssaysMolecular Docking Simulation030104 developmental biology030220 oncology & carcinogenesisPharmacophore modellingPath (graph theory)biology.proteinPharmacophoreProtein BindingCurrent Drug Discovery Technologies
researchProduct

Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy.

2013

Glycogen synthase kinase-3 (GSK-3) is a critical enzyme which participates in a complex array of important cellular processes and is often involved in various human diseases. It was first characterized in rat skeletal muscle as a serine/threonine (S/T) kinase that phosphorylated and inactivated glycogen synthase (GS). GS is the last enzyme in glycogen biosynthesis . Thus the initially identified role of GSK-3 was in metabolism. However, as we will soon see, GSK-3 has many diverse functions.

Cancer ResearchENZYMECarcinogenesisCancer therapymacromolecular substancesBiologymedicine.disease_causeGSK3law.inventionGlycogen Synthase Kinase 3GeneticlawGSK-3NeoplasmsGeneticsmedicineAnimalsHumansGenes Tumor SuppressorGenes tumor suppressorMolecular BiologyGeneCarcinogenesiAnimalNeoplasms therapyMolecular medicineMetabolismCancer researchNeoplasmMolecular MedicineSuppressorCarcinogenesisGlycogenHumanAdvances in biological regulation
researchProduct

Induction of DNA breaks and apoptosis in crosslink-hypersensitive V79 cells by the cytostatic drug beta-D-glucosyl-ifosfamide mustard.

2001

To study molecular aspects of cytotoxicity of the anticancer drug β-D-glucose-ifosfamide mustard we investigated the potential of the agent to induce apoptosis and DNA breakage. Since β-D-glucose-ifosfamide mustard generates DNA interstrand crosslinks, we used as an in vitro model system a pair of isogenic Chinese hamster V79 cells differing in their sensitivity to crosslinking agents. CL-V5B cells are dramatically more sensitive (30-fold based on D10 values) to the cytotoxic effects of β-D-glucose-ifosfamide mustard as compared to parental V79B cells. After 48 h of pulse-treatment with the agent, sensitive cells but not the resistant parental line undergo apoptosis and necrosis, with apopt…

Cancer ResearchProgrammed cell deathNecrosisDNA damageDNA repairAntineoplastic AgentsBiologychemistry.chemical_compoundCricetinaemedicineCytotoxic T cellAnimalsExperimental TherapeuticsIfosfamideDNA breaksCytotoxicityapoptosisDNAPhosphoramide MustardMolecular biologyNitrogen mustardEnzyme ActivationCross-Linking ReagentsGlucoseOncologyBiochemistrychemistryApoptosisCaspasescancer therapyPhosphoramide Mustardscyclophosphamidemedicine.symptomDNA DamageBritish journal of cancer
researchProduct

Abstract A22: PanDrugsDB: Identifying druggable genetic dependencies for personalized cancer therapy

2015

Abstract The paradigm of personalized medicine is the identification of the appropriate drug for the right patient, using molecular profiles. In Oncology, it is well established that the anticancer drugs are effective in only a small subset of patients. Moreover, many of the new targeted therapies inhibit specific proteins, and they are only effective in tumors that are genetically altered. Consequently, the success of personalized treatment depends on each individual molecular profile, which a priori can be considered as very heterogeneous. Here, we present a new computational approach (PanDrugsDB) based on the analysis and integration of genomic data (mutations, copy number variations or …

Cancer Researchbusiness.industryGenomic dataDruggabilityCancer therapyCancermedicine.diseaseBioinformaticsOncologyTumor progressionmedicineIdentification (biology)Copy-number variationPersonalized medicinebusinessMolecular Cancer Therapeutics
researchProduct